Ribosomal Protein L5 and L11 Mutations Are Associated with Cleft Palate and Abnormal Thumbs in Diamond-Blackfan Anemia Patients  by Gazda, Hanna T. et al.
REPORTRibosomal Protein L5 and L11 Mutations
Are Associated with Cleft Palate and Abnormal Thumbs
in Diamond-Blackfan Anemia Patients
Hanna T. Gazda,1,2,* Mee Rie Sheen,1 Adrianna Vlachos,3,4 Valerie Choesmel,5,6
Marie-Franc¸oise O’Donohue,5,6 Hal Schneider,1 Natasha Darras,1 Catherine Hasman,1 Colin A. Sieff,2,7
Peter E. Newburger,8 Sarah E. Ball,9 Edyta Niewiadomska,10 Michal Matysiak,10 Jan M. Zaucha,11
Bertil Glader,12 Charlotte Niemeyer,13 Joerg J. Meerpohl,13 Eva Atsidaftos,3,4 Jeffrey M. Lipton,3,4
Pierre-Emmanuel Gleizes,5,6 and Alan H. Beggs1,2
Diamond-Blackfan anemia (DBA), a congenital bone-marrow-failure syndrome, is characterized by red blood cell aplasia, macrocytic
anemia, clinical heterogeneity, and increased risk of malignancy. Although anemia is the most prominent feature of DBA, the disease
is also characterized by growth retardation and congenital anomalies that are present in ~30%–50% of patients. The disease has been
associated with mutations in four ribosomal protein (RP) genes, RPS19, RPS24, RPS17, and RPL35A, in about 30% of patients. However,
the genetic basis of the remaining 70% of cases is still unknown. Here, we report the second known mutation in RPS17 and probable
pathogenic mutations in three more RP genes, RPL5, RPL11, and RPS7. In addition, we identiﬁed rare variants of unknown signiﬁcance
in three other genes, RPL36, RPS15, and RPS27A. Remarkably, careful review of the clinical data showed that mutations in RPL5 are as-
sociated with multiple physical abnormalities, including craniofacial, thumb, and heart anomalies, whereas isolated thumb malforma-
tions are predominantly present in patients carrying mutations in RPL11. We also demonstrate that mutations of RPL5, RPL11, or RPS7
in DBA cells is associated with diverse defects in the maturation of ribosomal RNAs in the large or the small ribosomal subunit produc-
tion pathway, expanding the repertoire of ribosomal RNA processing defects associated with DBA.Diamond-Blackfan anemia (DBA) (MIM 105650) is an in-
herited congenital bone-marrow-failure syndrome, charac-
terized by normochromic macrocytic anemia and absence
or insufﬁciency of erythroid precursors in otherwise nor-
mocellular bone marrow.1 Although anemia is the most
prominent feature of DBA, the disease is also characterized
by growth retardation and congenital malformations, in
particular craniofacial, upper limb, heart, and urinary-sys-
tem defects, that are present in ~30%–50% of patients, re-
ﬂecting the fact that DBA is a broad disorder of develop-
ment.2–4 Laboratory ﬁndings such as increased mean
corpuscular volume (MCV), elevated erythrocyte adeno-
sine deaminase activity (eADA), and hemoglobin F are ob-
served in a majority of, but not in all, DBA patients.5,6 The
disease is clinically heterogenous, and within affected fam-
ilies, some individuals can exhibit mild or absent anemia,
with only subtle indications of erythroid abnormalities,
such as macrocytosis or elevated eADA and/or HbF. Addi-
tionally, increased risk of malignancy—in particular, AML
and solid tumors, including osteogenic sarcoma7,8—has
been associated with DBA. Approximately 90% of affected
individuals present during the ﬁrst year of life or in early
childhood, although patients with a ‘‘nonclassical’’ mildThe Americanphenotype are usually diagnosed later in life.3,4 The inci-
dence of DBA is 5–7 per million live births,2,3,9 affecting
both genders equally.4 Although most cases are sporadic,
about 10%–25%1,4 and up to, according to recent data,
even 45%10 are familial, with disease inherited in an auto-
somal-dominant pattern.
Heterozygous mutations in ribosomal protein genes
RPS19 (MIM 603474), RPS24 (MIM 602412), and RPS17
(MIM 180472), encoding RPs of the small ribosomal sub-
unit, and in RPL35A (MIM 180468), encoding an RP of
the large subunit, have been reported in about 30% of
DBA patients,6,10–15 suggesting that DBA is a disorder of
ribosomes. Haploinsufﬁciency of RPS19 and RPS24 has
been shown to be the basis for DBA in patients with muta-
tions of those genes. In a subset of patients, large deletions
and frameshift mutations lead to degradation of the
mutated transcripts.9,13,16,17 Recent studies have also dem-
onstrated that DBA missense mutations affect RPS19 con-
formation and stability, triggering proteasome-mediated
degradation or blocking RPS19’s incorporation into preri-
bosomes.18–20 Despite mutations identiﬁed in four genes,
no signiﬁcant phenotype-genotype correlations have
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RPL35Amutations are rare and have been reported in only
eight, one, and six patients, respectively.
RPS19 protein has been shown to play an important role
in 18S rRNA maturation in yeast and in human cells.21–24
Similarly, alterations of pre-RNA processing and small or
large ribosomal-subunit synthesis were demonstrated in
human cells with RPS24 and RPL35A deﬁciency, respec-
tively, further indicating that DBA is a disorder of ribo-
somes.15,25 Deﬁciency of RPS19 and RPL35A was shown
to cause increased apoptosis in hematopoietic cell lines
and in bone-marrow cells,15,26 and it has been suggested
that imbalance of the p53 family proteins is a mechanism
of abnormal embryogenesis and anemia in zebraﬁsh upon
perturbation of RPS19 expression.27
Here, we report the results of a large-scale screen of 24 ad-
ditional RP genes and of RPS17 (in which one mutation
among 24 tested patients was previously reported14) in
a cohort of DBA probands. Remarkably, we identiﬁed prob-
able pathogenic mutations in four of these genes, RPL5
(MIM 603634), RPL11 (MIM 604175), RPS7 (MIM
603658), and RPS17, representing ~16% of our patient co-
hort. In addition, we report possible single mutations in
three other RP genes, RPL36, RPS15 (MIM 180535), and
RPS27A (MIM 191343). In contrast to previously reported
data on patients with RPS19 mutations, mutations in
RPL5 are associated with multiple physical abnormalities,
including craniofacial, thumb, and heart anomalies,
whereas isolated thumb abnormalities are predominantly
present in patients carrying mutations in RPL11. We also
demonstrated defective rRNA maturation in RPL5-,
RPL11-, and RPS7-mutated DBA cells.
To test the hypothesis that mutations in other RP genes
can also cause DBA, we carried out direct sequencing of RP
genes, starting with what we considered to be the most
probable candidates. One hundred ninety-six DBA families
participated in the study. Thirty-six of them were multi-
plex families, and 160 included only one clinically affected
individual. All probands were negative for mutations in
RPS19 and RPS24, and 132 tested probands were negative
for mutations in RPL35A. Informed consent was obtained
from all patients and their family members participating
in the study under a protocol at Children’s Hospital Bos-
ton. The diagnosis of DBA in all probands was based on
normochromic, often macrocytic, anemia; reticulocytope-
nia; a low number or lack of erythroid precursors in bone
marrow; and, in some patients, congenital malformations
and elevated eADA.
Genomic DNA samples from 95 unrelated DBA probands
enrolled in the study were ampliﬁed by polymerase chain
reaction (PCR) and sequenced for mutations in 25 RP
genes. Initially, we sequenced three genes, RPS3A, RPS13,
and RPS16, which encode RPs and, like RPS19 and
RPS24, are involved in binding of initiation factor eIF-2
to the 40S subunit.28 Subsequently, we sequenced 11 RP
genes located on chromosome 19 (RPS5, RPS9, RPS11,
RPL13A, RPL18, RPL18A, RPL28, RPL40, RPS28, RPL36,
RPS15), because previous studies had reported linkage of770 The American Journal of Human Genetics 83, 769–780, DecembDBA to this chromosome in families that did not segregate
RPS19 mutations.11 Next, we screened ﬁve genes on chro-
mosome 1 (RPL5, RPL11, RPL22, RPS27, RPS8), because
Heyn et al. previously reported a pericentric inversion of
chromosome 1 in a DBA patient with cleft lip and palate
and a ventricular septal defect.29 RPS17 (chromosome 15)
was screened because Cmejla et al. reported one mutation
among 24 tested DBA patients,14 and RPL23 (chromosome
17) was screened because the RPS23 protein inhibits
MDM2-mediated p53 ubiquitination and degradation in
response to ribosomal stress in the same manner as RPL5
and RPL11.30 Subsequently, we have started sequencing
RP genes according to their chromosomal location, start-
ing with four genes on chromosome 2 (RPL31, RPL37A,
RPS7, RPS27A). Primers (sequences available on request)
were designed with Primer3 software for ampliﬁcation of
the coding exons and intron-exon boundaries of the above
genes. PCR products, between 200 and 600 bp, were robot-
ically prepared with a Tecan Genesis Workstation (Tecan,
Duram, NC), puriﬁed with Exo-SAP enzyme (USB, Cleve-
land, OH) and sequenced on both strands with an Applied
Biosystems 3730 DNA Analyzer (Applied Biosystems,
Foster City, CA). The chromatograms were analyzed with
Sequencher software, version 4.7 (Gene Codes, Ann Arbor,
MI). When a sequence change was identiﬁed in a given
gene, we sequenced an additional 101 samples from unre-
lated probands for mutations in this gene. Duplicate,
independent PCR products were sequenced to conﬁrm
the observed nucleotide changes in the probands. We se-
quenced DNA samples from at least 150 control individ-
uals, i.e., 300 chromosomes, to determine whether the
observed sequence variations were nonpathogenic vari-
ants. Subsequently, we sequenced DNA samples from
available family members to determine whether the muta-
tion cosegregated with the DBA phenotype within the
pedigree.
Interestingly, Heyn and colleagues reported a DBA pa-
tient with cleft lip and palate, VSD, and pericentric inver-
sion of chromosome 1, inv (1p-; 1qþ), resulting in the
shortened p arm and lengthened q arm.29 These ﬁndings
suggest that the gene causing DBA might be located on
chromosome 1. In accord with these ﬁndings, direct se-
quencing revealed multiple sequence changes in DBA
patients in coding regions and intron-exon boundaries
in two genes, RPL5 and RPL11, located on chromosome
1p (1p22.1 and 1p35-p36.1, respectively). In addition,
screening of 23 other RP genes revealed single sequence
changes in ﬁve of them, RPS7, RPS17, RPL36, RPS15, and
RPS27A, in DBA probands. In total, we found sequence
changes in seven out of 25 screened RP genes (Table 1).
DNA samples from available family members were also
screened, demonstrating that the identiﬁed sequence
changes cosegregated with the DBA phenotype within
the pedigrees (Tables 1–4).
To summarize, we identiﬁed sequence changes in RPL5
in 18 of 196 probands and in six additional family mem-
bers, for a total of 24 individuals with RPL5 sequenceer 12, 2008
changes. Seventeen of the identiﬁed changes cause prema-
ture termination either by nonsense or splice-site muta-
tions or deletions and/or insertions of 1–5 nucleotides
causing frameshifts. The 18th is a missense change,
418G/A, resulting in G140S substitution (Tables 1 and
2). All of these changes are unique, (i.e., not previously de-
scribed in the literature or databases), and 13 of them were
found in only a single kindred, whereas one was seen in
two and another in three apparently unrelated families.
Thirteen sequence changes were found in RPL11 among
196 DBA probands, and RPL11 sequence changes were
also identiﬁed in ﬁve other family members. These in-
cluded acceptor or donor splice-site mutations, deletions
or insertions of 1–4 nucleotides causing a frameshift, and
one nonsense mutation. All of these changes are also
unique, and 11 of them are distinct from each other, be-
cause two changes were seen in two unrelated probands
(Tables 1 and 3). Parental DNA was available in seven pro-
bands with RPL5 and in seven with RPL11 mutations. De
novo sequence changes were identiﬁed in four and six pro-
bands with sporadic disease, respectively, further support-
ing the assessment that these sequence changes are proba-
bly pathogenic mutations. The single sequence changes in
the ﬁve other RP genes, RPS7, RPS17, RPL36, RPS15, and
RPS27A, in DBA patients are summarized in Table 4. These
are a donor splice-site mutation in intron 2 of RPS7, a dele-
tion of 2 nt causing frameshifts in RPS17 and RPL36, as
well as two missense changes in RPS15 and RPS27A. Inter-
estingly, only one RPS17 mutation was identiﬁed among
24 tested patients14 and only one sequence change was
found in our patient cohort, demonstrating thatmutations
in RPS17 are rare events. None of the identiﬁed sequence
changes was found on the NCBI SNP lists, and none was
identiﬁed in at least 300 control chromosomes from a con-
trol population of similar, largely European origin. Since
we consider it possible that the three missense changes
in RPL5, RPS15, and RPS27A could be rare or private non-
Table 1. Summary of Sequence Changes in Seven RP Genes
Identified in 196 DBA Families
Gene
Symbol
No. of Tested
DNA Samples
from Unrelated
Probands
No. of Probands
with Mutations
(%)
No. of Subjects
with Mutations
Mutation
Types
RPL5 196 18 (9%) 24 nonsense,
missense,
splice site,
small indel
RPL11 196 13 (6.5%) 18 nonsense,
splice site,
small indel
RPS7 159 1 < 1% 1 splice site
RPS17 193 1 < 1% 1 small del
RPL36 132 1 < 1% 1 small del
RPS15 151 1 < 1% 1 missense
RPS27A 159 1 < 1% 2 missense
‘‘Indel’’ denotes insertion-deletion; ‘‘del’’ denotes deletion.The Americanpathogenic genetic variants, DNA samples carrying these
sequence changes are currently being screened for muta-
tions in the remaining 50 RP genes.
Remarkably, the RPL5 combined deletion-insertion
(c.498_502delTGTGG and c. 498, a 39 bp insertion) in
exon 5 was identiﬁed in a family with anemia, triphalan-
geal thumbs, cleft lip, and a heart abnormality (P15; Table
2), a class of symptoms previously described as Aase syn-
drome (MIM 105650).31 Strikingly, review of the available
medical data on 20 patients with mutations in RPL5 re-
vealed that the majority of them (14/20) have physical
malformations, including craniofacial, thumb, and heart
anomalies (Tables 2 and 5). Similarly, a majority of patients
with RPL11 mutations (12/18) presented with physical
malformations, whereas among 76 reported DBA patients
with RPS19 mutations, 35 (46%) presented with physical
malformations, including short stature6,10,12,32 (Tables 3
and 5). In general, regardless of genotype, congenital mal-
formations were described in 30%–50% of DBA pa-
tients.4,6,9,10 Remarkably, nine out of 14 patients with
RPL5 mutations and physical abnormalities have cleft lip
and/or palate or cleft soft palate, isolated or in combination
with other facial malformations—such as micrognathia,
hypertelorism, or mandibular hypoplasia with retrogna-
thia—and/or with other physical abnormalities, such as
heart or thumb anomalies (Table 5). In contrast, none of
the 12 patients with RPL11 mutations and malformations
have craniofacial abnormalities (p ¼ 0.007, Fisher’s exact
test [FET]). Moreover, none of the 35 reported patients
with RPS19 mutations and malformations6,10,12,32 pre-
sented with cleft lip and/or palate (p ¼ 9.745 3 107 for
RPL5 versus RPS19, FET) . Furthermore, among a group of
21 DBA patients with craniofacial abnormalities, reported
by the Diamond-Blackfan Anemia Registry (DBAR) of
North America, no RPS19 mutations were found, which
strongly suggested that the DBA phenotype associated
with cleft lip and/or palate is caused by gene(s) other
than RPS19.33 A report from DBAR revealed that 5.7% of
DBA patients present with cleft lip and/or palate4 and
some cases were reported with additional microtia and/or
ear abnormalities.34 In contrast, in the general population,
0.1%–0.2% of children are born with cleft lip and/or pal-
ate.35 Therefore, craniofacial clefting is clearly associated
with DBA, particularly with mutations in RPL5. Because
about half of DBA patients have unknown underlying
genetic causes of DBA, it is likely that mutations in other
DBA gene(s) yet to be discovered also cause craniofacial
abnormalities. Importantly, it is possible that some DBA
patients who present with craniofacial malformations
and with only subtle (such as macrocytosis and/or elevated
eADA) or no hematological abnormalities are underdiag-
nosed. RPL5 screening for mutations in these patients
could potentially help establish the diagnosis of DBA.
In addition to craniofacial malformations in patients
with RPL5 mutations, for patients whose medical records
are available, eight out of 20 patients with mutated RPL5
and eight out of 18 patients with mutated RPL11 haveJournal of Human Genetics 83, 769–780, December 12, 2008 771
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8Table 2. RPL5 Mutations in 18 Probands and Six Family Members from a Total of 196 Families Studied
Mutation
Type
Proband’s ID
(Gender)
Inheritance
Family
Members DNA Mutation
Exon/
Intron
Predicted
Amino Acid Change
Age at
Diagosis Malformation Status
Nonsense
mutation
P1 (F) sporadic m: normal seq c.48C/G Ex2 Y16Stop at birth NA
P2 (F) de novo f, m: normal
seq
c.67C/T Ex2 R23Stop 2mo cleft lip, cleft palate
P3 (F) sporadic c.228C/A Ex4 C76Stop 10 mo cleft palate, ASD, hypoplast
thumb, micrognathia, trach
Missense
mutation
P4 (M) familial m, s, b:
normal seq
c.418G/A Ex5 G140S 3 mo none
f c.418G/A Ex5 G140S no anemia NA
Deletion/
insertion
P5 (M)
sporadic
c.46_47 insA Ex2 Y16Stop at birth micrognathia, hypertelorism
cleft palate, triphalangeal r
thumb, widened webbed sp
between first and second to
hypospadias
P6 (F)
de novo
f, m:
normal seq
c.156_159
delAGTT
Ex3 Frameshift at
codon 52;
stop at 54
10 mo small jaw, cleft palate, trip
thumb, hip dysplasia, rib an
P7 (M)
sporadic
c.169_172
delAACA
Ex3 Frameshift at
codon 57;
stop at 68
at birth partial anomalous pulmona
venous return
P8 (M)
de novo
f, m, b:
normal seq
c.173 delG Ex3 Frameshift at
codon 58;
stop at 69
9 mo multiple congenital heart d
P9 (M)
sporadic
c.173_4 delGA Ex3 Frameshift at codon
58; stop at 111
NA long proximal thumb phala
bilateral, multiple congenit
defectsb
P10 (M)
sporadic
c.173_4 delGA Ex3 Frameshift at codon
58; stop at 111
10 mo small jaw, cleft palate,
bronchiopharyngeal malacia
mild hydrocephalus
P11 (F)
de novo
f, m, b, s:
normal seq
c.173_4 delGA Ex3 Frameshift at codon
58; stop at 111
NA NA
P12 (F)
familial
c.235_236 insT EX4 Frameshift at codon
79; stop at 112
11 yc cleft soft palate
m: familial c.235_236 insT EX4 Frameshift at codon
79; stop at 112
55 y none
P13 (F)
familial
c.235_236 insT EX4 Frameshift at codon
79; stop at 112
12 mo cleft palate, bifid uvula,
hypoplastic thumb,
m: familial c.235_236 insT EX4 Frameshift at codon
79; stop at 112
NA none
P14 (F)
familial
348_351
insTGGA
Ex5 Frameshift at codon
117; stop at 121
12 mo mandibular hypoplasia with
retrognathia, cleft palate w
uvula, dysplastic thumbs, A
12 mo mandibular hypoplasia with
retrognathia, cleft palate,
triphalangeal thumbs, persistent
foramen ovale, ASD type II
no therapy no therapy
20 yr none no therapy no therapy
NA triphalangeal thumbs, VSD responsive no therapy
NA cleft lip, triphalangeal thumbs unresponsive RBC trx
NA NA NA NA
NA inability to flex right distal
thumb phalanx
responsive SD NA
NA none responsive SD RBC trx
NA none responsive SD RBC trx
del, deletion; Ex, exon; In, intron; seq, sequence; mo, month; y, years; ND, not done; NA, not available;
l defect.
.s: familial ND ND
m: familial 348_351
insTGGA
Ex5 Frameshift at codon
117; stop at 121
P15 (M)
familial
f, m, s:
normal seq
c.498_502
delTGTGG and
39bp ins
Ex5
b: familial c.498_502
delTGTGG and
39bp ins
Ex5
d: familial c.498_502
delTGTGG and
39bp ins
Ex5
P16 (M)
sporadic
c.573_574 insG Ex. 6 Frameshift at codon
192; stop at 216
Splice-
site
mutation
P17 (M)
de novo
f, m, b:
normal seq
Donor splice site
IVS2 þ2t/g
Intr2
P18 (M)
sporadic
Donor splice site
IVS3 þ1g/t
Intr3
Abbreviations are as follows: P, proband; f, father; m, mother; s, sister; b, brother; d, daughter; ins, insertion;
SD, steroid dependent; RBC trx, red blood cell transfusions; ASD, atrial septal defect; VSD, ventricular septa
a Small patent ductus arteriosus, mild mitral valve prolapse, mild mitral regurgitation.
b Double outlet right ventricle, pulmonary stenosis, left pulmonary artery stenosis, patent ductus arteriosus
c macrocytic anemia diagnosed at age 11, DBA not diagnosed until years later.
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In, intron; seq, sequence; mo, month; y, years; NA, not available; SD,Table 3. RPL11 Mutations in 13 Probands and Five Family Members from a Total of 196 Families Studied
Mutation Type
Proband’s ID
(Gender)
Inheritance Family Members DNA Mutation
Exon/
Intron
Predicted Amino
Acid Change
Age at
Diagosis Malf
Nonsense
mutation
P19 (F) de novo f, m: normal seq c.223C/T Ex 3 R75Stop 2 mo triph
Deletion/
Insertion
P20 (F) familial c.60_61 delCT Ex2 Frameshift at codon 20;
stop at 53
9 mo VSD
pulm
m: familial c.60_61 delCT Ex2 Frameshift at codon 20;
stop at 53
NA triph
gm: familial c.60_61 delCT Ex2 Frameshift at codon 20;
stop at 53
NA triph
P21 (F) sporadic c.94_97 delAGAC Ex2 Frameshift at codon 32;
stop at 32
1 mo non
P22 (M) sporadic c.160_161 insA Ex3 Frameshift at codon 54;
stop at 66
NA abn
P23 (F) de novo f, m: normal seq c.290 delA Ex4 Frameshift at codon 97;
stop 14 aa behind wt stop
1 mo shor
P24 (M) de novo f, m: normal seq c.291_292 insA Ex4 Frameshift at codon 97;
stop at 120
NA hors
P25 (M) familial c.314_315 delTT Ex4 Frameshift at codon 105;
stop at 119
NA non
son c.314_315 delTT Ex4 Frameshift at codon 105;
stop at 119
NA sma
P26 (F) familial c.482_484 delAGG Ex5 161Edel 2 mo non
m: familial c.482_484 delAGG Ex5 161Edel NA non
Splice-site
mutation
P27 (F) de novo f, m: normal seq Donor splice site
IVS1 þ2t/c
In1 3 mo non
P28 (M) de novo f, m, b: normal seq Acceptor splice
site IVS2 -1g/a
In2 3 mo flat
sma
P29 (M) sporadic Acceptor splice
site IVS2 -1g/a
In2 2 y Tetr
bila
vesi
P30 (F) de novo f, m, b: normal seq Donor splice site
IVS4 þ1g/t
In4 2.5 mo hypo
flat
P31 (M) familial Donor splice site
IVS4 þ1g/a
In4 12 mo sma
Tetr
m: familial Donor splice site
IVS4 þ1g/a
In4 21 y left
shor
Abbreviations are as follows: P, proband; f, father; m, mother; gm, grandmother; s, sister; b, brother; ins, insertion; del, deletion; Ex, exon;
steroid dependent; RBC trx, red blood cell transfusions; VSD, ventricular septal defect.
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Table 4. Sequence Changes in RPS7, RPS17, RPL36, RPS15, and RPS27A in DBA Patients
Mutated
Gene
Proband’s
ID (Gender)
Inheritance
Family
Members DNA Mutation
Exon/
Intron
Predicted
Amino Acid
Change
Age at
Diagosis
Malformation
Status
Response at
First Steroid
Therapy
Present
Therapy
RPS7 P32 (M)
sporadic
s – normal
sequence
Donor splice site
IVS3þ1g>a
In3 NA none responsive SD steroid
therapy
RPS17 P33 (M)
de novo
f, m, s – normal
sequence
c. 200_201 delGA Ex3 Frameshift
at codon 67;
stop at 86
4 mo none responsive SD steroid
therapy
RPL36 P34 (M)
sporadic
c. 250_251 delGA Ex3 Frameshift
at codon 84;
stop 27 nt
behind wt
stop codon
2 mo left thumb
abnormality
responsive SD steroid
therapy
RPS15 P35 (F)
sporadic
c.208A/G Ex3 Met70Val 1 d truncus arteriosis
type 1, VSD,
colobomata, absent
right radius, ulna
and thumb, absent
left ulna, small
left thumb and 5th
finger, unilateral
absent fibulae and
club foot
unresponsive bone marrow
transplant
RPS27A P36 (F) m, b – normal
sequence
c.169T/C Ex4 Ser57Pro 15 mo none no therapy no therapy
familial f familial c.169T/C Ex4 Ser57Pro no DBA
diagnosis
none no therapy no therapy
Abbreviations are as follows: P, proband; f, father; m, mother; s, sister; b, brother; del, deletion; Ex, exon; In, intron; nt, nucleotide; wt, wild-type; mo,
month; d, day; NA, not available; SD, steroid-dependent; VSD, ventricular septal defect.thumb abnormalities, including triphalangeal or dysplas-
tic thumbs, additional bilateral small thumbs, and bilateral
long proximal thumb phalanges. In addition, two patients
with RPL11 mutation have ﬂat thenar muscles, one iso-
lated and the other associated with thumb abnormality.
In contrast, review of the literature reveals that various
thumb abnormalities were reported in only seven out
of 76 (9%) patients with RPS19 mutations6,10,12,32 (p ¼
0.0024 for RPL5 versus RPS19 and p ¼ 0.0012 for RPL11
versus RPS19, FET). Moreover, congenital heart defects
were found more often among patients with RPL5 muta-
tions (5/20) compared with RPL11 (3/18) and RPS19
(4/76) (Table 5) (p ¼ 0.017 for RPL5 versus RPS19, FET).
Strikingly, the majority (11/20) of patients with RPL5
mutations presented with multiple, severe abnormalities,
including craniofacial, heart, and/or thumb malforma-The Americantions. In contrast, patients with RPL11 and RPS19 muta-
tions who presented with multiple physical abnormalities
were uncommon: three patients out of 18 and 16 out of 76,
respectively6,10,12,32 (Table 5) (p ¼ 0.02 for RPL5 versus
RPL11 and p ¼ 0.0047 for RPL5 versus RPS19, FET).
Elevated eADA was found in all eight patients with RPL5
mutations and in eight patients with RPL11 mutations
for whom the results are available. Willig and colleagues6
described 11 families with RPS19 mutations and eADA
measurements. They have found cosegregation of the
RPS19mutations and high eADA in four families, although
partial cosegregation of the RPS19 mutations and elevated
eADA were found in seven other families.
Our ﬁnding of an RPL5mutation in the family ﬁrst diag-
nosed with Aase syndrome,31 as well as other mutations of
RPL5, RPL11, and, as described by Willigs and colleagues,6Table 5. Congenital Physical Abnormality in DBA Patients with RPL5, RPL11, and RPS19 Mutations
Patients with
Mutationsa
Patients with
Malformations
Cleft Lip
and/or Palateb
Thumb
Abnormalityb
Heart
Abnormalityb
Other Abnormalities,
Including Short Statureb
Multiple
Malformations
RPL5 20 14 9c 8 5 13 11
RPL11 18 12 0 8 3 4 3
RPS19d 76 35 0 7 4 47 16
a Total number of patients whose medical data are available.
b Isolated or in association with other abnormalities.
c Including two patients with soft cleft palate.
d Based on 6,10,12,32.Journal of Human Genetics 83, 769–780, December 12, 2008 775
Figure 1. Pre-rRNA Processing in Hu-
man Cells, According to Hadjiolova49
and Choesmel22
The mature 18S, 5.8S, and 28S rRNAs are
separated by ITS1 and ITS2 and flanked
by external transcribed spacers, 50-ETS
and 30-ETS. The red arrows and the numbers
in red indicate the cleavage sites. ‘‘A’’ and
‘‘B’’ represent two pathways of the rRNA
processing.RPS19 in DBA patients presenting with anemia and tripha-
langeal thumbs, conﬁrms the notion that the Aase syn-
drome is a subtype of DBA and not a separate syndrome.
Interestingly, 16 out of 18 patients with RPL5mutations
whose treatment data were available required steroid treat-
ment, and nine of them were responsive to the ﬁrst steroid
treatment, ﬁve were unresponsive, and one patient refused
steroid treatment, choosing red blood cell transfusions.
Similarly, 13 out of 17 patients with RPL11 mutations and
available data of their medical treatment also underwent
steroid therapy. Eleven of them responded well to the treat-
ment, and two were unresponsive. According to data from
the DBA Registry of North America, 79% of DBA patients
have been initially responsive to steroid, 17% have been
unresponsive, and 4% were never treated with steroids.4
In light of these data, steroid treatment of DBA patients
with RPL5 and RPL11 mutations seems to have a similar
outcome as that in the general DBA population. At present,
11 RPL5-mutation patients are dependent on red blood cell
transfusions, two are steroid-dependent, one patient
underwent stem cell transplantation, and three do not
need any treatment. Seven RPL11-mutation patients are
red blood cell transfusion-dependent, six are dependent
on steroid treatment, one patient underwent stem cell
transplantation, and three do not need any treatment.
Review of available medical data of 14 patients with
RPL5mutations revealed one patient withmelanoma. Sim-
ilarly, one patient out of 11 with RPL11 mutations and
available medical data had uterine cancer. None of the
patients with RPS7, RPS17, RPS15, RPL36, and RPS27A
sequence changes suffered from cancer. Data from the
DBA Registry of North America revealed eight DBA
patients among 420 registered as having hematopoietic,
nonhematopoietic, or mielodysplastic syndrome.4
DBA-associated ribosomal proteins RPS19, RPS24, and
RPL35A were shown to be required for pre-rRNA matura-
tion, a complex process that leads to the production of
three rRNAs from a common precursor (Figure 1). To deter-
mine whether DBA mutations in RPL5 and RPL11 affected
pre-rRNA maturation, we analyzed pre-rRNAs from lym-
phoblastoid cells established from DBA patients by north-
ern blotting, with probes complementary to the internal
transcribed spacer 2 (ITS2), and the signals were quantiﬁed
by phosphoimager. Cells mutated in either of these genes776 The American Journal of Human Genetics 83, 769–780, Decembdisplayed a conspicuous accumulation of 32S pre-rRNA
when compared to cells derived from control individuals,
this phenotype being more pronounced for mutations in
RPL5 (Figure 2A). In parallel, we also observed a higher
amount of 12S pre-rRNA (Figure 2A), as well as accumula-
tion of smaller precursors of 5.8S rRNA, which were not
detected in cells derived from the unaffected father of
one of the patients with RPL11mutation (Figure 2B). These
results indicate defective maturation of ITS2, both at the
initial endonucleolytic cleavage in the 32S pre-rRNA
and during subsequent processing steps. The ITS1 probe
also revealed a moderate increase in the levels of 30S
and 18S-E pre-rRNAs (data not shown), consistent with
several reports in yeast showing that perturbation of the
pre-60S particle maturation affects maturation of the 18S
rRNA.36
HeLa cells transfected with siRNAs complementary to
mRNAs encoding RPL5 and RPL11 had reduced levels of
28S and 5.8S when compared to controls. Consistently,
analysis of cytoplasmic ribosomes on sucrose gradient
showed low levels of free 60S subunit and formation of
half-mers in the polysomes upon knockdown of RPL5 or
RPL11 expression (Figure 2C), indicating that these pro-
teins are essential for synthesis of the 60S subunit. Indeed,
inhibition of RPL5 or RPL11 synthesis led to accumulation
of 32S and 12S pre-rRNAs, together with shorter precursors
to 5.8S (Figure 2D). Given the similarity of these pre-rRNA
processing defects with those observed above in lympho-
blastoid cells, we conclude that heterozygous mutation
of RPL5 and RPL11 in DBA has a direct impact on pre-
rRNA processing.
We applied a similar approach to evaluate the conse-
quence of the mutation in RPS7 found in a single DBA pa-
tient. Lymphoblastoid cells established from this patient’s
cells displayed higher levels of 45S and 30S pre-rRNAs
when compared to cells derived from an unaffected sibling
(Figure 2E). Accordingly, knockdown of RPS7 synthesis in
HeLa cells with siRNAs resulted in a strong defect in 50-
ETS processing. We observed accumulation of 45S and
30S pre-rRNAs and a marked decrease of the levels of the
41S, 21S, and 18S-E intermediates, whereas the amount
of precursors to the large ribosomal subunit RNAs was
unchanged (Figure 2E). This defective processing pattern
is very reminiscent of that observed upon depletion ofer 12, 2008
Figure 2. Impact of DBA Mutations in RPL5, RPL11, and RPS7 on Pre-rRNA Processing
(A) Northern blot analysis of total RNAs extracted from lymphoblastoid cells with mutations in RPL5 and RPL11. Precursor and mature
rRNAs were detected with probes complementary to the ITS2, 18S rRNA, and 28S rRNA sequences. Bar graphs show signal quantification
with a phosphoimager and include experiments from additional samples processed separately. Bars indicate variation of 32S/28S and
12S/28S intensity ratio relative to controls (means5 SD). Significance of the difference compared to controls was assessed with a Stu-
dent’s t test assuming nonequal variance (single asterisk indicates p% 0.05; double asterisk indicates p% 0.01; triple asterisk indicates
p % 0.001).
(B) Northern blot analysis of total RNAs fractionated on denaturing 6% polyacrylamide gel. After transfer, the blot was successively
hybridized with probes complementary either to the junction between 5.8S rRNA and ITS2 (probe 50-ITS2) or to 5.8S rRNA. 7SK RNA,
a stable and abundant noncoding RNA involved the regulation of RNA polymerase II, was chosen as a loading control.
(C) Analysis on sucrose gradient of cytoplasmic ribosomes isolated from HeLa cells 48 hr after transfection with siRNAs directed against
the mRNAs encoding RPL5 or RPL11. Arrowheads indicate polysomes containing half-mers. Control: transfection without siRNA. Expres-
sion of both siRNAs results in significant reduction of 60S particles. Differences in the extent of reduction are related to differing
efficiencies of the siRNAs used.
(D) Northern blot analysis of total RNAs from cells treated as in (C) with probes complementary to the ITS2, the 18S rRNA and the 28S rRNA
(1% agarose gel), or with probes complementary to the junction between the 5.8S rRNA and the ITS2 (probe 50-ITS2) and to the 5.8S (6%
polyacrylamide gel). The 7SK RNA is shown as a loading control for the polyacrylamide gel. Scrbl: scramble siRNA.
(E) Northern blot analysis of pre-rRNA processing in lymphoblastoid cell lines (LCL) with mutation in RPS7 and in HeLa cells transfected
with siRNAs targeting RPS7 mRNAs. The control RPS7þ/þ lymphoblastoid cells are derived from an unaffected sibling of the RPS7þ/mut
patient. Ctrl: HeLa cells transfected without siRNAs. Methods: The 21 nt siRNA duplexes with a 30 dTdT overhang, corresponding to L5
mRNA (50-AAGGGAGCTGTGGATGGAGGC-30)47 and to L11 mRNA (50-AAGGTGCGGGAGTATGAGTTA-30),48 were purchased from Eurogentec
(Seraing, Belgium) and transfected via electrotransformation, as described previously.42 Detection of pre-rRNA on northern blots was
performed as described previously50 with oligonucleotidic probes 18S, 28S, ITS1, ITS2b, and ITS2-d/e.42 For detection of ITS2, ITS2-b
and ITS2-d/e probes were mixed in equal amounts. The remaining probes had the following sequences: 50-ITS1, 50-CCTCGCCCT
CCGGGCTCCGTTAATGATC-30, 5.8S, 50-CAATGTGTCCTGCAATTCAC-30; 50-ITS2, 50-GGGGCGATTGATCGGCAAGCGACGCTC-30, 7SK (mix of two probes),
50-CATGGAGCGGTGAGGGAGGA-30, and 50-GTGTCTGGAGTCTTGGAAGC-30. For ribosome analysis on sucrose gradient, HeLa cells transfected with
siRNAs for 48 hr were treated with 100 mg/ml cycloheximide (Sigma Aldrich, St. Louis, MO) for 10 min and fractionated, and the cytoplasmic
fraction was analyzed on a 10%–50% sucrose gradient as described previously.42The American Journal of Human Genetics 83, 769–780, December 12, 2008 777
RPS24.25 As for mutations in RPL5 and RPL11, these results
strongly suggest that mutation of RPS7 in this DBA patient
directly affects maturation of the pre-rRNA.
RPL5, a 297 amino acid, 34 kDa protein component of
the 60S large ribosomal subunit, localizes to the cytoplasm
and the nucleolus. RPL5 is a nucleocytoplasmic shuttle
protein that plays an important role in 5S rRNA intracellu-
lar transport during assembly of the large ribosomal
subunit.37,38 Likewise, RPL11, a 178 amino acid, 21 kDa
protein, is also a component of the large ribosomal
subunit. RPL5 and RPL11 are closely connected during
ribosome biogenesis; it has been shown, by the recent
demonstration in yeast Saccharomyces cerevisiae, that they
form a subcomplex with the 5S rRNA prior to incorpora-
tion into preribosomes.39 RPS19 deﬁciency was shown
to affect 18S rRNA maturation and small-ribosomal-
subunit formation in yeast and in human cells.22–24,40
We showed that mutations of RPS24 in human cells alter
maturation of the 18S rRNA at an earlier stage than do
mutations in RPS19.25 Similarly, alterations of pre-RNA
processing and large-ribosomal-subunit synthesis were
demonstrated in cell lines and in DBA cells with RPL35A
deﬁciency.15
Here, we show that mutations in RPL5 and RPL11 in
DBA cells lead to accumulation of the 32S and 12S interme-
diates of 28S rRNA and smaller precursors on the 5.8S rRNA
maturation pathways. As shown by the analysis of cyto-
plasmic ribosomes on sucrose gradient, both RPL5 and
RPL11 proteins are essential for rRNA maturation and
60S ribosomal subunit formation. RPL5 and RPL11 knock-
down induces accumulation of precursors to 5.8S rRNA,
whereas siRNA-mediated knockdown of RPL35A tran-
scripts results in a decrease of these rRNA species,15 indicat-
ing that these RPs fulﬁll different functions in pre-rRNA
processing, in agreement with recently published data.41
RPS7 mutation, in turn, affects the 50-ETS cleavage, similar
to RPS24 mutation. The role of RPS15 in nuclear export of
the 40S subunit has been documented in mammalian
cells42 and in Saccharomyces cerevisiae,21,43 whereas deple-
tion of RPS31, the ortholog of RPS27A in yeast, is also nec-
essary for production of the 40S ribosomal subunit.43 The
ﬁndings of several ribosomal protein genes mutated in
DBA, which subsequently cause aberrant rRNAmaturation
and small or large subunit formations, supports a hypothe-
sis of a unifying model of DBA as a disorder of ribosome
biogenesis that might stem from diverse defects in pre-
rRNA processing.
Interestingly, RPL11 has been recently implicated in the
negative regulation of c-Myc function. The c-Myc onco-
protein enhances ribosome biogenesis and promotes cell
growth. Overexpression of c-Myc was shown to alter ribo-
some production and tumorigenesis, whereas overexpres-
sion of RPL11 inhibits these actions of c-Myc. In contrast,
reduction of RPL11 expression increases c-Myc-induced
transcription and cell proliferation.44 Both RPL5 and
RPL11, as well as RPL23, were shown to inhibit MDM2-
mediated p53 ubiquitination and degradation in response778 The American Journal of Human Genetics 83, 769–780, Decemto ribosomal stress by restoring p53-mediated transactiva-
tion, accumulating p21 protein levels, and inducing
a p53-dependent cell-cycle arrest.30,45–48 It will be interest-
ing to evaluate the effects of RPL5 and RPL11 mutations of
these pathways in future studies for assessment of their po-
tential role(s) in apoptosis and in promoting tumorigenesis
in patients with DBA.
In summary,we found thatmutations inRPL5 andRPL11
are present in about 9% and 6.5% of our DBA proband co-
hort, respectively. After correcting for the fact that our study
population was prescreened for RPS19, RPS24, and RPL35A
mutations, we estimate that RPL5 and RPL11mutations are
present in about 6.6% and in 4.8% of the overall DBA pop-
ulation, respectively. Remarkably, RPL5 and RPL11 muta-
tions are associated with physical malformations in about
70% and 67% of mutated patients, respectively, as com-
pared to only 46% of patients with RPS19 mutations,
none of whom have been reported to have cleft lip and/or
cleft palate.6,10,12,32 Thus, toour knowledge,RPL5 is theﬁrst
ribosomal protein gene to be associatedwith cleft lip and/or
cleft palate abnormalities inDBApatients.Moreover,muta-
tions in RPL5 appear to cause a more severe phenotype,
compared tomutations inRPL11 andRPS19, whereasmuta-
tions in RPL11 are predominantly associated with thumb
abnormalities. Thedata donotpermit deﬁnitive determina-
tion of pathogenicity for the mutations that we found in
RPL36,RPS15, andRPS27A, whichwill require further study
by groups with access to additional DBA patient cohorts.
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